
Dario Giugliano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6882550/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of a Mediterranean-Style Diet on Endothelial Dysfunction and Markers of Vascular Inflammation in the Metabolic Syndrome. JAMA - Journal of the American Medical Association, 2004, 292, 1440.	3.8	1,819
2	Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans. Circulation, 2002, 106, 2067-2072.	1.6	1,717
3	Oxidative Stress and Diabetic Vascular Complications. Diabetes Care, 1996, 19, 257-267.	4.3	1,644
4	Effect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women. JAMA - Journal of the American Medical Association, 2003, 289, 1799.	3.8	1,275
5	Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients. Diabetes, 2008, 57, 1349-1354.	0.3	977
6	Reduction of Inflammatory Cytokine Concentrations and Improvement of Endothelial Functions in Obese Women After Weight Loss Over One Year. Circulation, 2002, 105, 804-809.	1.6	932
7	The Effect of Mediterranean Diet on Metabolic Syndrome and its Components. Journal of the American College of Cardiology, 2011, 57, 1299-1313.	1.2	917
8	Metabolic Syndrome and Risk of Cancer. Diabetes Care, 2012, 35, 2402-2411.	4.3	900
9	Effect of Lifestyle Changes on Erectile Dysfunction in Obese Men. JAMA - Journal of the American Medical Association, 2004, 291, 2978.	3.8	732
10	The Effects of Diet on Inflammation. Journal of the American College of Cardiology, 2006, 48, 677-685.	1.2	654
11	Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: Role of fat and carbohydrate meals. Journal of the American College of Cardiology, 2002, 39, 1145-1150.	1.2	503
12	Olive oil and health: Summary of the II international conference on olive oil and health consensus report, Jaén and Córdoba (Spain) 2008. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 284-294.	1.1	449
13	Regression of Carotid Atherosclerosis by Control of Postprandial Hyperglycemia in Type 2 Diabetes Mellitus. Circulation, 2004, 110, 214-219.	1.6	406
14	Effects of a Mediterranean-Style Diet on the Need for Antihyperglycemic Drug Therapy in Patients With Newly Diagnosed Type 2 Diabetes. Annals of Internal Medicine, 2009, 151, 306.	2.0	380
15	A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ Open, 2015, 5, e008222.	0.8	368
16	Effect of Postprandial Hypertriglyceridemia and Hyperglycemia on Circulating Adhesion Molecules and Oxidative Stress Generation and the Possible Role of Simvastatin Treatment. Diabetes, 2004, 53, 701-710.	0.3	335
17	Diabetes mellitus, hypertension, and cardiovascular disease: Which role for oxidative stress?. Metabolism: Clinical and Experimental, 1995, 44, 363-368.	1.5	317
18	Vascular Effects of Acute Hyperglycemia in Humans Are Reversed by <scp>l</scp> -Arginine. Circulation, 1997, 95, 1783-1790.	1.6	300

#	Article	IF	CITATIONS
19	Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients. American Journal of Clinical Nutrition, 1993, 57, 650-656.	2.2	299
20	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. Nutrition Reviews, 2017, 75, 307-326.	2.6	294
21	Association of Low Interleukin-10 Levels with the Metabolic Syndrome in Obese Women. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1055-1058.	1.8	281
22	Effect of Atorvastatin and Irbesartan, Alone and in Combination, on Postprandial Endothelial Dysfunction, Oxidative Stress, and Inflammation in Type 2 Diabetic Patients. Circulation, 2005, 111, 2518-2524.	1.6	281
23	Mediterranean Diet and Weight Loss: Meta-Analysis of Randomized Controlled Trials. Metabolic Syndrome and Related Disorders, 2011, 9, 1-12.	0.5	275
24	Vitamin E Reduction of Protein Glycosylation in Diabetes: New Prospect for Prevention of Diabetic Complications?. Diabetes Care, 1991, 14, 68-72.	4.3	260
25	Metabolic and Cardiovascular Effects of Carvedilol and Atenolol in Non-Insulin-Dependent Diabetes Mellitus and Hypertension. Annals of Internal Medicine, 1997, 126, 955.	2.0	260
26	Acute Hyperglycemia Induces Nitrotyrosine Formation and Apoptosis in Perfused Heart From Rat. Diabetes, 2002, 51, 1076-1082.	0.3	256
27	Impairment of Endothelial Functions by Acute Hyperhomocysteinemia and Reversal by Antioxidant Vitamins. JAMA - Journal of the American Medical Association, 1999, 281, 2113.	3.8	246
28	Oxidative stress and insulin action: is there a relationship?. Diabetologia, 1996, 39, 357-363.	2.9	244
29	High Proportions of Erectile Dysfunction in Men With the Metabolic Syndrome. Diabetes Care, 2005, 28, 1201-1203.	4.3	231
30	Weight Loss Reduces Interleukin-18 Levels in Obese Women. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3864-3866.	1.8	218
31	Original Research—Outcomes Assessment: Development and Validation of a 6-Item Version of the Female Sexual Function Index (FSFI) as a Diagnostic Tool for Female Sexual Dysfunction. Journal of Sexual Medicine, 2010, 7, 1139-1146.	0.3	215
32	Effect of Weight Loss on Cardiac Synchronization and Proinflammatory Cytokines in Premenopausal Obese Women. Diabetes Care, 2004, 27, 47-52.	4.3	212
33	Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women. Diabetes Care, 1993, 16, 1387-1390.	4.3	210
34	Circulating Adhesion Molecules in Humans. Circulation, 2000, 101, 2247-2251.	1.6	208
35	Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. American Journal of Clinical Nutrition, 2003, 78, 1135-1140.	2.2	205
36	Association of body weight with sexual function in women. International Journal of Impotence Research, 2007, 19, 353-357.	1.0	205

#	Article	IF	CITATIONS
37	The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia, 2000, 43, 571-575.	2.9	196
38	The effect of Mediterranean diet on the development of type 2 diabetes mellitus: A meta-analysis of 10 prospective studies and 136,846 participants. Metabolism: Clinical and Experimental, 2014, 63, 903-911.	1.5	194
39	Acute hyperglycemia induces an oxidative stress in healthy subjects. Journal of Clinical Investigation, 2001, 108, 635-636.	3.9	191
40	Diet and inflammation: a link to metabolic and cardiovascular diseases. European Heart Journal, 2006, 27, 15-20.	1.0	187
41	The metabolic syndrome and inflammation: association or causation?. Nutrition, Metabolism and Cardiovascular Diseases, 2004, 14, 228-232.	1.1	185
42	Glucose metabolism and hyperglycemia. American Journal of Clinical Nutrition, 2008, 87, 217S-222S.	2.2	184
43	Obesity, the metabolic syndrome, and sexual dysfunction. International Journal of Impotence Research, 2005, 17, 391-398.	1.0	177
44	Mediterranean diet and metabolic diseases. Current Opinion in Lipidology, 2008, 19, 63-68.	1.2	175
45	Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. Journal of Thrombosis and Haemostasis, 2004, 2, 1453-1459.	1.9	170
46	Prevention and control of type 2 diabetes by Mediterranean diet: A systematic review. Diabetes Research and Clinical Practice, 2010, 89, 97-102.	1.1	170
47	Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. European Journal of Clinical Pharmacology, 1993, 44, 107-112.	0.8	164
48	Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes. Diabetes Care, 2013, 36, 2346-2350.	4.3	158
49	Impairment of insulin secretion in man by nifedipine. European Journal of Clinical Pharmacology, 1980, 18, 395-398.	0.8	156
50	Daily Vitamin E Supplements Improve Metabolic Control But Not Insulin Secretion in Elderly Type II Diabetic Patients. Diabetes Care, 1993, 16, 1433-1437.	4.3	155
51	Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2020, 43, 1146-1156.	4.3	155
52	Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia, 2002, 45, 1172-1181.	2.9	153
53	Effects of Stress Hyperglycemia on Acute Myocardial Infarction: Role of inflammatory immune process in functional cardiac outcome. Diabetes Care, 2003, 26, 3129-3135.	4.3	153
54	Post-Meal Glucose Peaks at Home Associate with Carotid Intima-Media Thickness in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1345-1350.	1.8	152

#	Article	IF	CITATIONS
55	Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine, 2013, 44, 634-647.	1.1	152
56	The Effects of a Mediterranean Diet on the Need for Diabetes Drugs and Remission of Newly Diagnosed Type 2 Diabetes: Follow-up of a Randomized Trial. Diabetes Care, 2014, 37, 1824-1830.	4.3	149
57	The vascular effects of L-Arginine in humans. The role of endogenous insulin Journal of Clinical Investigation, 1997, 99, 433-438.	3.9	146
58	Determinants of female sexual dysfunction in type 2 diabetes. International Journal of Impotence Research, 2010, 22, 179-184.	1.0	144
59	Anti-oxidants show an anti-hypertensive effect in diabetic and hypertensive subjects. Clinical Science, 1991, 81, 739-742.	1.8	143
60	Determinants of erectile dysfunction in type 2 diabetes. International Journal of Impotence Research, 2010, 22, 204-209.	1.0	141
61	Erectile and endothelial dysfunction in Type II diabetes: a possible link. Diabetologia, 2001, 44, 1155-1160.	2.9	140
62	Endothelial Microparticles Correlate with Endothelial Dysfunction in Obese Women. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3676-3679.	1.8	140
63	Evidence That Hyperglycemia After Recovery From Hypoglycemia Worsens Endothelial Function and Increases Oxidative Stress and Inflammation in Healthy Control Subjects and Subjects With Type 1 Diabetes. Diabetes, 2012, 61, 2993-2997.	0.3	136
64	Mediterranean diet improves erectile function in subjects with the metabolic syndrome. International Journal of Impotence Research, 2006, 18, 405-410.	1.0	133
65	Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. Journal of Endocrinological Investigation, 2004, 27, 665-669.	1.8	130
66	Hydroxychloroquine in Decompensated, Treatment-Refractory Noninsulin-Dependent Diabetes Mellitus. Annals of Internal Medicine, 1990, 112, 678.	2.0	126
67	Obesity and sexual dysfunction, male and female. International Journal of Impotence Research, 2008, 20, 358-365.	1.0	126
68	Hyperglycemia in Streptozotocin-Induced Diabetic Rat Increases Infarct Size Associated With Low Levels of Myocardial HO-1 During Ischemia/Reperfusion. Diabetes, 2005, 54, 803-810.	0.3	125
69	Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine, 2014, 45, 28-36.	1.1	123
70	New Insights on Nonâ€enzymatic Glycosylation May Lead to Therapeutic Approaches for the Prevention of Diabetic Complications. Diabetic Medicine, 1992, 9, 297-299.	1.2	119
71	The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an "Endothelial Resistance―to Glucagon-Like Peptide 1 in Diabetes. Diabetes Care, 2011, 34, 697-702.	4.3	119
72	Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes, Obesity and Metabolism, 2012, 14, 228-233.	2.2	119

#	Article	IF	CITATIONS
73	Mediterranean Diet for Primary Prevention of Cardiovascular Disease. New England Journal of Medicine, 2013, 369, 672-677.	13.9	119

Evidence for a relationship between oxidative stress and insulin action in non-insulin-dependent (type) Tj ETQq0 0 0 rgBT /Overlock 10 T

75	Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes. Diabetes Care, 2011, 34, 510-517.	4.3	116
76	Metabolic Control May Influence the Increased Superoxide Generation in Diabetic Serum. Diabetic Medicine, 1991, 8, 540-542.	1.2	115
77	Effect of metformin on food intake in obese subjects. European Journal of Clinical Investigation, 1998, 28, 441-446.	1.7	115
78	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3231-3244.	1.8	113
79	Effect of dietary antioxidants on postprandial endothelial dysfunction induced by a high-fat meal in healthy subjects. American Journal of Clinical Nutrition, 2003, 77, 139-143.	2.2	112
80	The Ubiquitin-Proteasome System and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Rosiglitazone Treatment. Diabetes, 2006, 55, 622-632.	0.3	112
81	Effect of metabolic syndrome and its components on prostate cancer risk: Meta-analysis. Journal of Endocrinological Investigation, 2013, 36, 132-139.	1.8	112
82	Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies. Endocrine, 2014, 47, 107-116.	1.1	112
83	Metabolic syndrome and postmenopausal breast cancer. Menopause, 2013, 20, 1301-1309.	0.8	110
84	Prevention of Type 2 Diabetes by Dietary Patterns: A Systematic Review of Prospective Studies and Meta-Analysis. Metabolic Syndrome and Related Disorders, 2010, 8, 471-476.	0.5	109
85	Expression of Angiogenic Factors During Acute Coronary Syndromes in Human Type 2 Diabetes. Diabetes, 2004, 53, 2383-2391.	0.3	108
86	Mediterranean diet and metabolic syndrome: An updated systematic review. Reviews in Endocrine and Metabolic Disorders, 2013, 14, 255-263.	2.6	106
87	GLPâ€l receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated metaâ€analysis including the REWIND and PIONEER 6 trials. Diabetes, Obesity and Metabolism, 2019, 21, 2576-2580.	2.2	104
88	GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovascular Diabetology, 2021, 20, 189.	2.7	104
89	Effects of Intensive Lifestyle Changes on Erectile Dysfunction in Men. Journal of Sexual Medicine, 2009, 6, 243-250.	0.3	103
90	From inflammation to sexual dysfunctions: a journey through diabetes, obesity, and metabolic syndrome. Journal of Endocrinological Investigation, 2018, 41, 1249-1258.	1.8	101

#	Article	IF	CITATIONS
91	Pulsatile Insulin Delivery has Greater Metabolic Effects than Continuous Hormone Administration in Man: Importance of Pulse Frequency. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 607-615.	1.8	100
92	Advancing age and insulin resistance: new facts about an ancient history. European Journal of Clinical Investigation, 1999, 29, 758-769.	1.7	100
93	Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2017, 40, 614-624.	4.3	97
94	The metabolic syndrome: a cause of sexual dysfunction in women. International Journal of Impotence Research, 2005, 17, 224-226.	1.0	96
95	Revisitation of autoimmune hypophysitis: knowledge and uncertainties on pathophysiological and clinical aspects. Pituitary, 2016, 19, 625-642.	1.6	94
96	Diabetes and Aging: From Treatment Goals to Pharmacologic Therapy. Frontiers in Endocrinology, 2019, 10, 45.	1.5	94
97	Morphine, Opioid Peptides, and Pancreatic Islet Function. Diabetes Care, 1984, 7, 92-98.	4.3	92
98	Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. Diabetologia, 1986, 29, 644-647.	2.9	92
99	Simultaneous Control of Hyperglycemia and Oxidative Stress Normalizes Endothelial Function in Type 1 Diabetes. Diabetes Care, 2007, 30, 649-654.	4.3	92
100	Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2011, 13, 594-603.	2.2	92
101	Glucose "peak―and glucose "spike― Impact on endothelial function and oxidative stress. Diabetes Research and Clinical Practice, 2008, 82, 262-267.	1.1	90
102	Genetics of medullary thyroid cancer: An overview. International Journal of Surgery, 2017, 41, S2-S6.	1.1	89
103	Hemodynamic effects of acute hyperglycemia in type 2 diabetic patients. Diabetes Care, 2000, 23, 658-663.	4.3	88
104	Mediterranean diet for type 2 diabetes: cardiometabolic benefits. Endocrine, 2017, 56, 27-32.	1.1	88
105	Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia, 1988, 31, 889-91.	2.9	87
106	Cytokine Milieu Tends Toward Inflammation in Type 2 Diabetes. Diabetes Care, 2003, 26, 1647-1647.	4.3	87
107	Absence of Inducible Nitric Oxide Synthase Reduces Myocardial Damage During Ischemia Reperfusion in Streptozotocin-Induced Hyperglycemic Mice. Diabetes, 2004, 53, 454-462.	0.3	85
108	Adherence to a Mediterranean diet and glycaemic control in Type 2 diabetes mellitus. Diabetic Medicine, 2009, 26, 900-907.	1.2	84

#	Article	IF	CITATIONS
109	Sexual dysfunction in women with cancer: a systematic review with meta-analysis of studies using the Female Sexual Function Index. Endocrine, 2016, 54, 329-341.	1.1	84
110	Lowering fatty acids potentiates acute insulin response in first degree relatives of people with Type II diabetes. Diabetologia, 1998, 41, 1127-1132.	2.9	83
111	Role of Free Fatty Acids on Cardiac Autonomic Nervous System in Noninsulin-Dependent Diabetic Patients: Effects of Metabolic Control. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2769-2774.	1.8	83
112	Dietary antioxidants for cardiovascular prevention. Nutrition, Metabolism and Cardiovascular Diseases, 2000, 10, 38-44.	1.1	83
113	Oxidative stress in the metabolic syndrome. Journal of Endocrinological Investigation, 2006, 29, 791-795.	1.8	80
114	Morning Blood Pressure Peak, QT Intervals, and Sympathetic Activity in Hypertensive Patients. Hypertension, 2003, 41, 237-243.	1.3	79
115	Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. American Journal of Hypertension, 2004, 17, 223-227.	1.0	77
116	Body weight and glucose metabolism have a different effect on circulating levels of ICAM-1, E-selectin, and endothelin-1 in humans. European Journal of Endocrinology, 2004, 150, 195-200.	1.9	76
117	Diabetes mellitus and hypertension: the possible role of hyperglycaemia through oxidative stress. Diabetologia, 1993, 36, 265-266.	2.9	75
118	Mediterranean diet, endothelial function and vascular inflammatory markers. Public Health Nutrition, 2006, 9, 1073-1076.	1.1	75
119	Clinical Inertia as a Clinical Safeguard. JAMA - Journal of the American Medical Association, 2011, 305, 1591.	3.8	74
120	Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. American Journal of Physiology - Endocrinology and Metabolism, 1995, 268, E1167-E1173.	1.8	73
121	Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Metaâ€Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials. Journal of the American Heart Association, 2019, 8. e012356.	1.6	73
122	Pharmacokinetic-Pharmacodynamic Relationships of Acarbose. Clinical Pharmacokinetics, 1996, 30, 94-106.	1.6	72
123	Role of Adipokines in the Obesity???Inflammation Relationship: The Effect of Fat Removal. Plastic and Reconstructive Surgery, 2006, 118, 1048-1057.	0.7	72
124	Metabolic syndrome and cancer: "The common soil hypothesis― Diabetes Research and Clinical Practice, 2018, 143, 389-397.	1.1	70
125	Metformin Improves Hemodynamic and Rheological Responses to L-Arginine in NIDDM Patients. Diabetes Care, 1996, 19, 934-939.	4.3	69
126	Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. American Journal of Hypertension, 2005, 18, 308-318.	1.0	69

#	Article	IF	CITATIONS
127	Are there specific treatments for the metabolic syndrome?. American Journal of Clinical Nutrition, 2008, 87, 8-11.	2.2	68
128	Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine, 2016, 51, 417-428.	1.1	68
129	Impaired insulin-induced erythrocyte magnesium accumulation is correlated to impaired insulin-mediated glucose disposal in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 1988, 31, 910-5.	2.9	66
130	Effects of Perindopril and Carvedilol on Endothelium-Dependent Vascular Functions in Patients With Diabetes and Hypertension. Diabetes Care, 1998, 21, 631-636.	4.3	66
131	Mediterranean diet and type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2014, 30, 34-40.	1.7	66
132	Plasma vitamin C affects glucose homeostasis in healthy subjects and in non-insulin-dependent diabetics. American Journal of Physiology - Endocrinology and Metabolism, 1994, 266, E261-E268.	1.8	63
133	Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes-a randomized controlled trial. Diabetes, Obesity and Metabolism, 2011, 13, 439-445.	2.2	63
134	A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open, 2015, 5, e005892-e005892.	0.8	63
135	Insights into the relationships between diabetes, prediabetes, and cancer. Endocrine, 2017, 56, 231-239.	1.1	63
136	SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovascular Diabetology, 2021, 20, 236.	2.7	63
137	Mediterranean diet and the metabolic syndrome. Molecular Nutrition and Food Research, 2007, 51, 1268-1274.	1.5	62
138	Circulating CD34+KDR+ Endothelial Progenitor Cells Correlate with Erectile Function and Endothelial Function in Overweight Men. Journal of Sexual Medicine, 2009, 6, 107-114.	0.3	60
139	Effects of Mediterranean diet on sexual function in people with newly diagnosed type 2 diabetes: The MÃ^DITA trial. Journal of Diabetes and Its Complications, 2016, 30, 1519-1524.	1.2	60
140	Diabetic Foot Problems During the COVID-19 Pandemic in a Tertiary Care Center: The Emergency Among the Emergencies. Diabetes Care, 2020, 43, e123-e124.	4.3	60
141	FFAs and QT Intervals in Obese Women with Visceral Adiposity: Effects of Sustained Weight Loss Over 1 Year. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2080-2083.	1.8	59
142	Effect of a Mediterranean diet on endothelial progenitor cells and carotid intima-media thickness in type 2 diabetes: Follow-up of a randomized trial. European Journal of Preventive Cardiology, 2017, 24, 399-408.	0.8	59
143	Mediterranean diet improves sexual function in women with the metabolic syndrome. International Journal of Impotence Research, 2007, 19, 486-491.	1.0	58
144	Dietary Factors, Mediterranean Diet and Erectile Dysfunction. Journal of Sexual Medicine, 2010, 7, 2338-2345.	0.3	58

#	Article	IF	CITATIONS
145	Influence of short-term selenium supplementation on the natural course of Hashimoto's thyroiditis: clinical results of a blinded placebo-controlled randomized prospective trial. Journal of Endocrinological Investigation, 2017, 40, 83-89.	1.8	58
146	High glucose induces ventricular instability and increases vasomotor tone in rats. Diabetologia, 2001, 44, 464-470.	2.9	57
147	Long-Term Glycemic Control Influences the Long-Lasting Effect of Hyperglycemia on Endothelial Function in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2751-2756.	1.8	57
148	Evidence for peripheral impaired glucose handling in patients with connective tissue diseases. Metabolism: Clinical and Experimental, 1991, 40, 902-907.	1.5	56
149	Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: Role of tumor necrosis factor-α. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 274-279.	1.1	56
150	Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open, 2014, 4, e005442-e005442.	0.8	56
151	Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans. Diabetologia, 1990, 33, 163-167.	2.9	55
152	Obesity, the Metabolic Syndrome, and Sexual Dysfunction in Men. Clinical Pharmacology and Therapeutics, 2011, 90, 169-173.	2.3	55
153	Particulate matter pollutants and risk of type 2 diabetes: a time for concern?. Endocrine, 2016, 51, 32-37.	1.1	54
154	The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovascular Diabetology, 2022, 21, 42.	2.7	54
155	Effects of α- and β-Adrenergic Inhibition and Somatostatin on Plasma Glucose, Free Fatty Acids, Insulin, Glucagon, and Growth Hormone Responses to Prostaglandin E ₁ in Man*. Journal of Clinical Endocrinology and Metabolism, 1979, 48, 302-308.	1.8	52
156	Glucose tolerance and hormonal responses in heroin addicts. A possible role for endogenous opiates in the pathogenesis of non-insulin-dependent diabetes. Metabolism: Clinical and Experimental, 1983, 32, 1163-1165.	1.5	52
157	Glutathione Infusion Potentiates Glucose-Induced Insulin Secretion in Aged Patients With Impaired Glucose Tolerance. Diabetes Care, 1992, 15, 1-7.	4.3	52
158	Endothelial microparticles correlate with erectile dysfunction in diabetic men. International Journal of Impotence Research, 2007, 19, 161-166.	1.0	52
159	Lifestyle and metabolic approaches to maximizing erectile and vascular health. International Journal of Impotence Research, 2012, 24, 61-68.	1.0	52
160	Tolrestat for Mild Diabetic Neuropathy: A 52-Week, Randomized, Placebo-Controlled Trial. Annals of Internal Medicine, 1993, 118, 7.	2.0	51
161	Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review. Diabetes Research and Clinical Practice, 2011, 92, 1-10.	1.1	50
162	Addition of Neutral Protamine Lispro Insulin or Insulin Glargine to Oral Type 2 Diabetes Regimens for Patients with Suboptimal Glycemic Control. Annals of Internal Medicine, 2008, 149, 531.	2.0	49

#	Article	IF	CITATIONS
163	ORIGINAL RESEARCH—ERECTILE DYSFUNCTION: Adherence to Mediterranean Diet and Erectile Dysfunction in Men with Type 2 Diabetes. Journal of Sexual Medicine, 2010, 7, 1911-1917.	0.3	49
164	Dietary factors in erectile dysfunction. International Journal of Impotence Research, 2006, 18, 370-374.	1.0	48
165	Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes. Journal of Endocrinological Investigation, 2019, 42, 495-503.	1.8	48
166	Impaired Glucose Metabolism in Heroin and Methadone Users. Hormone and Metabolic Research, 1987, 19, 430-433.	0.7	47
167	Telmisartan Shows an Equivalent Effect of Vitamin C in Further Improving Endothelial Dysfunction After Glycemia Normalization in Type 1 Diabetes. Diabetes Care, 2007, 30, 1694-1698.	4.3	46
168	The effect of acetylsalicylic acid on insulin response to glucose and arginine in normal man. Diabetologia, 1978, 14, 359-362.	2.9	45
169	Resting Metabolic Rate and Respiratory Quotient in Human Longevity. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 409-413.	1.8	45
170	Hyperlipidemia and Sexual Function in Premenopausal Women. Journal of Sexual Medicine, 2009, 6, 1696-1703.	0.3	45
171	Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism: Clinical and Experimental, 1989, 38, 1162-1163.	1.5	44
172	The involvement of the opioid system in human obesity: a study in normal weight relatives of obese people Journal of Clinical Endocrinology and Metabolism, 1996, 81, 713-718.	1.8	44
173	Peripheral Diabetic Neuropathy. Drugs, 1997, 54, 414-421.	4.9	44
174	ORIGINAL RESEARCH—WOMEN'S SEXUAL HEALTH: Adherence to Mediterranean Diet and Sexual Function in Women with Type 2 Diabetes. Journal of Sexual Medicine, 2010, 7, 1883-1890.	0.3	44
175	GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Current Medical Research and Opinion, 2011, 27, 1519-1528.	0.9	44
176	Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors. Endocrine, 2014, 46, 43-51.	1.1	44
177	Mediterranean diet cools down the inflammatory milieu in type 2 diabetes: the MÉDITA randomized controlled trial. Endocrine, 2016, 54, 634-641.	1.1	43
178	Advantageous Metabolic Effects of Pulsatile Insulin Delivery in Noninsulin-Dependent Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 1005-1010.	1.8	42
179	Mediterranean Diet and Cardiovascular Health. Annals of the New York Academy of Sciences, 2005, 1056, 253-260.	1.8	42
180	Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis. Stroke, 2020, 51, 666-669.	1.0	42

#	Article	IF	CITATIONS
181	Impaired Insulin Secretion in Human Diabetes Mellitus: The Effect of Naloxone-Induced Opiate Receptor Blockade. Diabetes, 1982, 31, 367-370.	0.3	41
182	Chronic intake of pharmacological doses of vitamin E might be useful in the therapy of elderly patients with coronary heart disease. American Journal of Clinical Nutrition, 1995, 61, 848-852.	2.2	41
183	Effect of a multidisciplinary program of weight reduction on endothelial functions in obese women. Journal of Endocrinological Investigation, 2003, 26, RC5-RC8.	1.8	41
184	Phenotypic Assessment of Endothelial Microparticles in Diabetic and Nondiabetic Men with Erectile Dysfunction. Journal of Sexual Medicine, 2008, 5, 1436-1442.	0.3	41
185	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Design, Development and Therapy, 2013, 7, 989.	2.0	41
186	The Squatting Test: A Useful Tool to Assess Both Parasympathetic and Sympathetic Involvement of the Cardiovascular Autonomic Neuropathy in Diabetes. Diabetes, 1994, 43, 607-612.	0.3	40
187	Sympathovagal Balance, Nighttime Blood Pressure, and QT Intervals in Normotensive Obese Women. Obesity, 2003, 11, 653-659.	4.0	40
188	Inflammation Warms Up the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, e143.	1.1	40
189	Acetyl-L-carnitine for symptomatic diabetic neuropathy. Diabetologia, 1995, 38, 123-123.	2.9	39
190	Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: A population-based study. Diabetes Research and Clinical Practice, 2015, 108, 157-163.	1.1	39
191	Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope. Diabetes, Obesity and Metabolism, 2019, 21, 1081-1087.	2.2	39
192	Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care, 2006, 29, 1071-6.	4.3	39
193	Glucose utilization from dialysate in patients on continuous ambulatory peritoneal dialysis (CAPD). International Journal of Artificial Organs, 1979, 2, 119-24.	0.7	38
194	Long-Term Effect of Mediterranean-Style Diet and Calorie Restriction on Biomarkers of Longevity and Oxidative Stress in Overweight Men. Cardiology Research and Practice, 2011, 2011, 1-5.	0.5	37
195	Induced Hyperglycemia Alters Antithrombin III Activity but not its Plasma Concentration in Healthy Normal Subjects. Diabetes, 1987, 36, 320-323.	0.3	36
196	Tolrestat in the Primary Prevention of Diabetic Neuropathy. Diabetes Care, 1995, 18, 536-541.	4.3	36
197	Characterization of a Novel Polymorphism in PPARG Regulatory Region Associated with Type 2 Diabetes and Diabetic Retinopathy in Italy. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-7.	3.0	36
198	Sexual function in young women with type 1 diabetes: the METRO study. Journal of Endocrinological Investigation, 2017, 40, 169-177.	1.8	36

#	Article	IF	CITATIONS
199	Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine, 2018, 61, 23-27.	1.1	36
200	A Possible Role for λ-Aminobutyric Acid in the Control of the Endocrine Pancreas*. Journal of Clinical Endocrinology and Metabolism, 1982, 54, 1145-1149.	1.8	35
201	Sensitivity to β-endorphin as a cause of human obesity. Metabolism: Clinical and Experimental, 1987, 36, 974-978.	1.5	35
202	l-arginine but not d-arginine stimulates insulin-mediated glucose uptake. Metabolism: Clinical and Experimental, 1997, 46, 1068-1073.	1.5	35
203	LL-Paraoxonase Genotype Is Associated with a More Severe Degree of Homeostasis Model Assessment IR in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 222-225.	1.8	35
204	Sexual Dysfunction in Women With the Metabolic Syndrome. Diabetes Care, 2005, 28, 756-756.	4.3	35
205	Pioglitazone Reduces Endothelial Microparticles in the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1926-1926.	1.1	35
206	SUGAR AND WOUND HEALING. Lancet, The, 1985, 326, 663-665.	6.3	34
207	Diet and the Metabolic Syndrome. Metabolic Syndrome and Related Disorders, 2007, 5, 291-296.	0.5	34
208	Hyperglycemia Counterbalances the Antihypertensive Effect of Glutathione in Diabetic Patients: Evidence Linking Hypertension and Glycemia Through the Oxidative Stress in Diabetes Mellitus. Journal of Diabetes and Its Complications, 1997, 11, 250-255.	1.2	33
209	Mediterranean Diet and the Metabolic Syndrome: The End of the Beginning. Metabolic Syndrome and Related Disorders, 2010, 8, 197-200.	0.5	33
210	Relationship between albuminuric CKD and diabetic retinopathy in a real-world setting of type 2 diabetes: Findings from No blind study. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 923-930.	1.1	33
211	Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies. Cardiovascular Diabetology, 2020, 19, 115.	2.7	33
212	Increased glycosylated haemoglobin A1 in opiate addicts: Evidence for a hyperglycaemic effect of morphine. Diabetologia, 1982, 22, 379.	2.9	32
213	Elevated plasma fatty acid concentrations prolong cardiac repolarization in healthy subjects. American Journal of Clinical Nutrition, 2001, 73, 27-30.	2.2	32
214	Obesity, cytokines and endothelial dysfunction: A link for the raised cardiovascular risk associated with visceral obesity. Journal of Endocrinological Investigation, 2002, 25, 646-649.	1.8	32
215	Plasma Interleukin-18 Concentrations Are Elevated in Type 2 Diabetes. Diabetes Care, 2004, 27, 272-272.	4.3	32
216	Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI. Endocrine, 2014, 46, 256-262.	1.1	32

#	Article	IF	CITATIONS
217	Pituitary dysfunction in granulomatosis with polyangiitis. Pituitary, 2017, 20, 594-601.	1.6	32
218	Free and fixedâ€ratio combinations of basal insulin and GLPâ€1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and metaâ€analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2018, 20, 2309-2313.	2.2	32
219	Opioid peptides and metabolic regulation. Diabetologia, 1988, 31, 3-15.	2.9	32
220	Primary role of glucagon release in the effect of β-endorphin on glucose homeostasis in normal man. European Journal of Endocrinology, 1987, 115, 161-169.	1.9	31
221	Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity. Diabetologia, 1990, 33, 205-207.	2.9	31
222	Abnormal Rheologic Effects of Glyceryl Trinitrate in Patients with Non-Insulin-Dependent Diabetes Mellitus and Reversal by Antioxidants. Annals of Internal Medicine, 1995, 123, 338.	2.0	31
223	Should we abandon statins in the prevention of bone fractures?. Endocrine, 2013, 44, 326-333.	1.1	31
224	Metabolic syndrome and cancer: holistic or reductionist?. Endocrine, 2014, 45, 362-364.	1.1	31
225	Oxidative stress and insulin action: is there a relationship?. Diabetologia, 1996, 39, 357-363.	2.9	31
226	Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovascular Diabetology, 2021, 20, 210.	2.7	31
227	Acetylsalicylic Acid Restores Acute Insulin Response Reduced by Furosemide in Man. Diabetes, 1979, 28, 841-845.	0.3	30
228	Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials. International Journal of Clinical Practice, 2011, 65, 602-612.	0.8	30
229	Fracture Risk and Bone Mineral Density in Metabolic Syndrome: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3306-3314.	1.8	30
230	Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study. Endocrine, 2016, 52, 244-252.	1.1	30
231	Erectile dysfunction in young men with type 1 diabetes. International Journal of Impotence Research, 2017, 29, 17-22.	1.0	30
232	Class effect for SGLT-2 inhibitors: a tale of 9 drugs. Cardiovascular Diabetology, 2019, 18, 94.	2.7	30
233	<scp>S</scp> odiumâ€glucose coâ€transporterâ€2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated metaâ€analysis. Diabetes, Obesity and Metabolism, 2021, 23, 1672-1676.	2.2	30
234	Efficacy of SGLT-2 inhibitors in older adults with diabetes: Systematic review with meta-analysis of cardiovascular outcome trials. Diabetes Research and Clinical Practice, 2020, 162, 108114.	1.1	29

#	Article	IF	CITATIONS
235	Acute Pressor and Hormonal Effects of β-Endorphin at High Doses in Healthy and Hypertensive Subjects: Role of Opioid Receptor Agonism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5167-5174.	1.8	28
236	Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis. Journal of Endocrinological Investigation, 2019, 42, 1165-1169.	1.8	28
237	Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2019, 21, 1790-1800.	2.2	28
238	Calcitonin, A Diabetogenic Hormone?*. Journal of Clinical Endocrinology and Metabolism, 1981, 53, 318-323.	1.8	27
239	Hyperglycemia and Obesity as Determinants of Glucose, Insulin, and Glucagon Responses toβ-Endorphin in Human Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 1122-1128.	1.8	27
240	Pharmacological Doses of Oxytocin Affect Plasma Hormone Levels Modulating Glucose Homeostasis in Normal Man. Hormone Research, 1988, 30, 10-16.	1.8	27
241	Calcitonin in painful diabetic neuropathy. Lancet, The, 1992, 339, 746-747.	6.3	27
242	L-arginine for testing endothelium-dependent vascular functions in health and disease American Journal of Physiology - Endocrinology and Metabolism, 1997, 273, E606.	1.8	27
243	Acute effects of β-endorphin on cardiovascular function in patients with mild to moderate chronic heart failure. American Heart Journal, 2004, 148, 530.	1.2	27
244	Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert Opinion on Drug Safety, 2016, 15, 77-83.	1.0	27
245	Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?. Endocrine, 2017, 55, 360-365.	1.1	27
246	Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A metaâ€analysis with metaâ€regression. Diabetes, Obesity and Metabolism, 2020, 22, 1397-1405.	2.2	27
247	Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 17.	2.7	27
248	Effect of irbesartan on nitrotyrosine generation in non-hypertensive diabetic patients. Diabetologia, 2004, 47, 1535-1540.	2.9	26
249	Metabolic Control May Alter Antithrombin III Activity but Not Its Plasma Concentration in Diabetes: A Possible Role for Nonenzymatic Glycosylation. Diabetes Care, 1986, 9, 32-35.	4.3	25
250	Decreased insulin clearance as a feature of essential hypertension Journal of Clinical Endocrinology and Metabolism, 1992, 74, 144-149.	1.8	25
251	Effect of acute hyperglycaemia, longâ€ŧerm glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics. Diabetic Medicine, 2010, 27, 911-917.	1.2	25
252	Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials. Endocrine, 2019, 65, 15-24.	1.1	25

#	Article	IF	CITATIONS
253	Effects of Salicylate, Tolbutamide, and Prostaglandin E2 on Insulin Responses to Glucose in Noninsulin- Dependent Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 160-166.	1.8	24
254	β-Endorphin Infusion Restores Acute Insulin Responses to Glucose in Type-2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 944-948.	1.8	24
255	Altered Metabolic and Hormonal Responses to Epinephrine andβ-Endorphin in Human Obesity. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 238-244.	1.8	24
256	Autonomic dysfunction associates with prolongation of QT intervals and blunted night BP in obese women with visceral obesity. Journal of Endocrinological Investigation, 2002, 25, RC32-RC35.	1.8	24
257	M40403 prevents myocardial injury induced by acute hyperglycaemia in perfused rat heart. European Journal of Pharmacology, 2004, 497, 65-74.	1.7	24
258	Vitamin D Deficiency in Type 2 Diabetic Patients with Hypogonadism. Journal of Sexual Medicine, 2014, 11, 536-542.	0.3	24
259	Vitamin D and autoimmunity: what happens in autoimmune polyendocrine syndromes?. Journal of Endocrinological Investigation, 2015, 38, 629-633.	1.8	24
260	The Effects of Subcutaneous Insulin Infusion Versus Multiple Insulin Injections on Glucose Variability in Young Adults with Type 1 Diabetes: The 2-Year Follow-Up of the Observational METRO Study. Diabetes Technology and Therapeutics, 2018, 20, 117-126.	2.4	24
261	Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney. Cardiovascular Diabetology, 2020, 19, 35.	2.7	24
262	Metabolic Effects of Liposuction — Yes or No?. New England Journal of Medicine, 2004, 351, 1354-1357.	13.9	23
263	Sexual dysfunction and the Mediterranean diet. Public Health Nutrition, 2006, 9, 1118-1120.	1.1	23
264	Increased platelet reactivity in Klinefelter men: something new to consider. Andrology, 2015, 3, 876-881.	1.9	23
265	Remission of type 2 diabetes: is bariatric surgery ready for prime time?. Endocrine, 2015, 48, 417-421.	1.1	23
266	Anti-inflammatory Effect of Mediterranean Diet in Type 2 Diabetes Is Durable: 8-Year Follow-up of a Controlled Trial. Diabetes Care, 2016, 39, e44-e45.	4.3	23
267	Influence of acetylsalicylic acid on plasma glucose, insulin, glucagon, and growth hormone levels following tolbutamide stimulation in man. Metabolism: Clinical and Experimental, 1979, 28, 887-889.	1.5	22
268	Hypomagnesemia in Relation to Diabetic Retinopathy. Diabetes Care, 1982, 5, 558-559.	4.3	22
269	Dual Effect of Beta-Endorphin on Insulin Secretion in Man. Hormone and Metabolic Research, 1987, 19, 502-503.	0.7	22
270	Stress Hyperglycemia, Inflammation, and Cardiovascular Events. Diabetes Care, 2003, 26, 1650-1651.	4.3	22

#	Article	IF	CITATIONS
271	Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?. Acta Diabetologica, 2009, 46, 173-181.	1.2	22
272	Unhealthy diets: a common soil for the association of metabolic syndrome and cancer. Endocrine, 2014, 46, 39-42.	1.1	22
273	Primary Prevention of Sexual Dysfunction With Mediterranean Diet in Type 2 Diabetes: The MÃ^DITA Randomized Trial. Diabetes Care, 2016, 39, e143-e144.	4.3	22
274	More sugar? No, thank you! The elusive nature of low carbohydrate diets. Endocrine, 2018, 61, 383-387.	1.1	22
275	Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Diabetes Care, 2021, 44, 1353-1360.	4.3	22
276	Prostaglandin E1 inhibits glucose-induced insulin secretion in man. Prostaglandins, Leukotrienes and Essential Fatty Acids, 1978, 1, 165-166.	1.2	21
277	Inhibitory effect of enkephalin on insulin secretion in healthy subjects and in non insulin-dependent diabetic subjects. Metabolism: Clinical and Experimental, 1987, 36, 286-289.	1.5	21
278	Elevated plasma free fatty acid concentrations do not modify cardiac repolarization in patients treated by electrolyte-glucose-insulin infusion. Journal of Endocrinological Investigation, 2002, 25, RC19-RC22.	1.8	21
279	Elevated post-prandial free fatty acids are associated with cardiac sympathetic overactivity in Type II diabetic patients. Diabetologia, 2002, 45, 1737-1738.	2.9	21
280	Lifestyle/Dietary Recommendations for Erectile Dysfunction and Female Sexual Dysfunction. Urologic Clinics of North America, 2011, 38, 293-301.	0.8	21
281	Circulating endothelial progenitor cells in type 1 diabetic patients with erectile dysfunction. Endocrine, 2015, 49, 415-421.	1.1	21
282	Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer antiâ€hyperglycaemic drug matters?. Diabetes, Obesity and Metabolism, 2020, 22, 149-157.	2.2	21
283	The BB-Paraoxonase Genotype Is Associated with Impaired Brachial Reactivity after Acute Hypertriglyceridemia in Healthy Subjects. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1078-1082.	1.8	20
284	Lifestyle approach for type 2 diabetes and metabolic syndrome. Current Atherosclerosis Reports, 2008, 10, 523-528.	2.0	20
285	Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes?. Endocrine, 2013, 44, 343-345.	1.1	20
286	Impaired insulin secretion in human diabetes mellitus. The effect of naloxone-induced opiate receptor blockade. Diabetes, 1982, 31, 367-370.	0.3	20
287	A Role for Beta-Endorphin in the Pathogenesis of Human Obesity?. Hormone and Metabolic Research, 1991, 23, 251-256.	0.7	19
288	Impaired Glucose Metabolism and Reduced Insulin Clearance in Elderly Hypertensives. American Journal of Hypertension, 1992, 5, 345-353.	1.0	19

#	Article	IF	CITATIONS
289	The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?. Expert Opinion on Biological Therapy, 2014, 14, 799-808.	1.4	19
290	Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes. Endocrine, 2016, 53, 220-226.	1.1	19
291	Gender-differences in glycemic control and diabetes related factors in young adults with type 1 diabetes: results from the METRO study. Endocrine, 2018, 61, 240-247.	1.1	19
292	The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 154, 101-115.	1.1	19
293	The involvement of the opioid system in human obesity: a study in normal weight relatives of obese people. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 713-718.	1.8	19
294	ENDOGENOUS OPIATES, HEROIN ADDICTION, AND NON-INSULIN-DEPENDENT DIABETES. Lancet, The, 1985, 326, 769-770.	6.3	18
295	Effects of Oxytocin Delivery on Counter-Regulatory Hormone Response in Insulin-Dependent (Type 1) Diabetic Subjects. Hormone Research, 1989, 31, 250-255.	1.8	18
296	Mean arterial blood pressure and serum levels of the molar ratio of insulin-like growth factor-1 to its binding protein-3 in healthy centenarians. Journal of Hypertension, 1999, 17, 67-73.	0.3	18
297	Whole-grain intake cools down inflammation. American Journal of Clinical Nutrition, 2006, 83, 1440-1441.	2.2	18
298	Low-Carbohydrate Diet and Coronary Heart Disease in Women. New England Journal of Medicine, 2007, 356, 750-752.	13.9	18
299	Interleukin-20 circulating levels in obese women: Effect of weight loss. Nutrition, Metabolism and Cardiovascular Diseases, 2010, 20, 180-185.	1.1	18
300	Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes. Expert Opinion on Biological Therapy, 2012, 12, 209-221.	1.4	18
301	Premature Ejaculation is Associated with Glycemic Control in Type 1 Diabetes. Journal of Sexual Medicine, 2015, 12, 93-99.	0.3	18
302	GLP-1 receptor agonists vs. SGLT-2 inhibitors:Âthe gap seems to be leveling off. Cardiovascular Diabetology, 2021, 20, 205.	2.7	18
303	Hyperglycemia and QT interval: time for re-evaluation. Diabetes, Nutrition & Metabolism, 2001, 14, 63-5.	0.4	18
304	Impaired insulin response to glucose but not to arginine in heroin addicts. Journal of Endocrinological Investigation, 1986, 9, 353-357.	1.8	17
305	The Role of Hyperglycaemiaâ€induced Alterations of Antithrombin III and Factor X Activation in the Thrombin Hyperactivity of Diabetes Mellitus. Diabetic Medicine, 1990, 7, 343-348.	1.2	17
306	Possible Role for Increased C4b-Binding–Protein Level in Acquired Protein S Deficiency in Type I Diabetes. Diabetes, 1990, 39, 447-449.	0.3	17

#	Article	IF	CITATIONS
307	Effect of insulin on blood rheology in non-diabetic subjects and in patients with type 2 diabetes mellitus. , 1997, 14, 959-963.		17
308	Quantitative Sensory and Autonomic Testing in Nondiabetic Women with Sexual Dysfunction. Journal of Sexual Medicine, 2007, 4, 1367-1372.	0.3	17
309	Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review. Journal of Diabetes and Its Complications, 2011, 25, 275-281.	1.2	17
310	Characterization of pituitary cells targeted by antipituitary antibodies in patients with isolated autoimmune diseases without pituitary insufficiency may help to foresee the kind of future hypopituitarism. Pituitary, 2014, 17, 457-463.	1.6	17
311	Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in TypeÂ2 Diabetes. Diabetes Therapy, 2022, 13, 619-634.	1.2	17
312	Glycosylated haemoglobin and reticulocyte count in diabetes. Diabetologia, 1982, 22, 223.	2.9	16
313	Â-Endorphin-Induced Inhibition and Stimulation of Insulin Secretion in Normal Humans Is Clucose Dependent. Diabetes, 1988, 37, 1265-1270.	0.3	16
314	Physiological elevations of plasma β-endorphin alter glucose metabolism in obese, but not normal-weight, subjects. Metabolism: Clinical and Experimental, 1992, 41, 184-190.	1.5	16
315	Initiation and Gradual Intensification of Premixed Insulin Lispro Therapy Versus Basal ± Mealtime Insulin in Patients With Type 2 Diabetes Eating Light Breakfasts. Diabetes Care, 2014, 37, 372-380.	4.3	16
316	Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In <i>Standards of Medical Care in Diabetes—2016</i> . Diabetes Care 2016;39(Suppl. 1):S52–S59. Diabetes Care, 2016, 39, e86-e87.	4.3	16
317	Modulation by verapamil of insulin and glucagon secretion in man. Acta Diabetologica, 1981, 18, 163-171.	1.2	15
318	A role for endogenous prostaglandin E in biphasic pattern of insulin release in humans. American Journal of Physiology - Endocrinology and Metabolism, 1983, 245, E591-E597.	1.8	15
319	Depressed antithrombin III biological activity in opiate addicts Journal of Clinical Pathology, 1984, 37, 1040-1042.	1.0	15
320	Increased alpha2-macroglobulin in diabetes: A hyperglycemia related phenomenon associated with reduced antithrombin III activity. Acta Diabetologica Latina, 1989, 26, 147-154.	0.2	15
321	Correspondence. Atherosclerosis, 2000, 149, 223-224.	0.4	15
322	Pizza and Vegetables Don't Stick to the Endothelium. Circulation, 2001, 104, E34-5.	1.6	15
323	Effect of rimonabant on weight reduction and cardiovascular risk. Lancet, The, 2005, 366, 367-368.	6.3	15
324	Rosiglitazone Cools Down Inflammation in the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1413-1414.	1.1	15

#	Article	IF	CITATIONS
325	Longitudinal behavior of autoimmune GH deficiency: from childhood to transition age. European Journal of Endocrinology, 2016, 174, 381-387.	1.9	15
326	FFAs and QT Intervals in Obese Women with Visceral Adiposity: Effects of Sustained Weight Loss Over 1 Year. , 0, .		15
327	Influence of acetylsalicylic acid on glucose turnover in normal man. Diabète & Métabolisme, 1982, 8, 279-82.	0.3	15
328	Hemodynamic and Metabolic Effects of Transdermal Clonidine in Patients With Hypertension and Non–Insulin-Dependent Diabetes Mellitus. American Journal of Hypertension, 1998, 11, 184-189.	1.0	14
329	Beneficial Effects of a Dietary Approaches to Stop Hypertension Eating Plan on Features of the Metabolic Syndrome: Response to Azdbakht et al Diabetes Care, 2006, 29, 954-955.	4.3	14
330	Dietary Glycemic Index and Glycemic Load Are Associated with Metabolic Control in Type 2 Diabetes: The CAPRI Experience. Metabolic Syndrome and Related Disorders, 2010, 8, 255-261.	0.5	14
331	When Metformin Fails in Type 2 Diabetes Mellitus. Archives of Internal Medicine, 2011, 171, 365.	4.3	14
332	Healthy lifestyle for metabolic health: no more excuse!. Endocrine, 2014, 46, 176-178.	1.1	14
333	Clucose variability inversely associates with endothelial progenitor cells in type 1 diabetes. Endocrine, 2015, 48, 342-345.	1.1	14
334	The residual cardiorenal risk in type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 36.	2.7	14
335	Persistence of altered metabolic responses to beta-endorphin after normalization of body weight in human obesity. European Journal of Endocrinology, 1991, 124, 159-165.	1.9	14
336	Hyperinsulinemia in hypertension: Increased secretion, reduced clearance or both?. Journal of Endocrinological Investigation, 1993, 16, 315-321.	1.8	13
337	Impairment of coronary circulation by acute hyperhomocysteinaemia and reversal by antioxidant vitamins. Journal of Internal Medicine, 2004, 256, 398-405.	2.7	13
338	Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in typeÂ1 diabetes. Journal of Thrombosis and Haemostasis, 2009, 7, 1228-1230.	1.9	13
339	Anti-Pituitary Antibodies and Hypogonadotropic Hypogonadism in Type 2 Diabetes: In Search of a Role. Diabetes Care, 2013, 36, e116-e117.	4.3	13
340	Acetylsalicyclic acid restores acute insulin response reduced by furosemide in man. Diabetes, 1979, 28, 841-845.	0.3	13
341	Evidence for a possible role of oxygen free radicals in the abnormal functional arterial vasomotion in insulin dependent diabetes. DiabĂïte & Métabolisme, 1990, 16, 318-22.	0.3	13
342	Impaired insulin secretion in human diabetes mellitus. II. A possible role for prostaglandins. Prostaglandins, Leukotrienes and Essential Fatty Acids, 1981, 6, 41-50.	1.2	12

#	Article	IF	CITATIONS
343	Sodium salicylate restores the impaired insulin response to glucose and improves glucose tolerance in heroin addicts. Acta Diabetologica Latina, 1987, 24, 205-212.	0.2	12
344	Comparison of Nitrendipine and Cilazapril in Patients With Hypertension and Non-Insulin-Dependent Diabetes Mellitus. American Journal of Hypertension, 1993, 6, 927-932.	1.0	12
345	Impairment of Coronary Circulation by Acute Hyperhomocysteinemia in Type 2 Diabetic Patients. Diabetes Care, 2004, 27, 2055-2056.	4.3	12
346	Increased consumption of green leafy vegetables, but not fruit, vegetables or fruit and vegetables combined, is associated with reduced incidence of type 2 diabetes. Evidence-Based Medicine, 2011, 16, 27-28.	0.6	12
347	Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diabetes, Obesity and Metabolism, 2011, 13, 1149-1157.	2.2	12
348	Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up. Diabà te & Métabolisme, 1986, 12, 315-8.	0.3	12
349	Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide. Diab̕te & M̩tabolisme, 1993, 19, 225-9.	0.3	12
350	Influence of ozone on haemoglobin oxygen affinity in type-2 diabetic patients with peripheral vascular disease: in vitro studies. DiabA¨te & MA©tabolisme, 1995, 21, 252-5.	0.3	12
351	Prostaglandins and the alpha-cell. Prostaglandins, Leukotrienes and Essential Fatty Acids, 1981, 6, 283-297.	1.2	11
352	Normalization by Sodium Salicylate of the Impaired Counterregulatory Glucagon Response to Hypoglycemia in Insulin-dependent Diabetes: A Possible Role for Endogenous Prostaglandins. Diabetes, 1985, 34, 521-525.	0.3	11
353	Heparin Preserves Antithrombin III Biological Activity from Hyperglycemia-Induced Alterations in Insulin-Dependent Diabetics. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1986, 16, 458-464.	0.5	11
354	Opiate Addict as Diabetic Patient?. Diabetes Care, 1988, 11, 443-443.	4.3	11
355	Effects of oxytocin upon the endocrine pancreas secretion and glucose turnover in normal man. European Journal of Endocrinology, 1990, 123, 504-510.	1.9	11
356	Nicardipine does not cause deterioration of glucose homoeostasis in man: A placebo controlled study in elderly hypertensives with and without diabetes mellitus. European Journal of Clinical Pharmacology, 1992, 43, 39-45.	0.8	11
357	Detection of Early Sympathetic Cardiovascular Neuropathy by Squatting Test in NIDDM. Diabetes Care, 1994, 17, 149-151.	4.3	11
358	Simvastatin normalizes QTc dispersion and reduces ventricular electrical instability in isolated hypercholesterolemia. Journal of Endocrinological Investigation, 2002, 25, RC16-RC18.	1.8	11
359	Basal Supplementation of Insulin Lispro Protamine Suspension Versus Insulin Glargine and Detemir for Type 2 Diabetes. Diabetes Care, 2012, 35, 2698-2705.	4.3	11
360	Type 2 diabetes and cardiovascular prevention: the dogmas disputed. Endocrine, 2018, 60, 224-228.	1.1	11

#	Article	IF	CITATIONS
361	The squatting test. A useful tool to assess both parasympathetic and sympathetic involvement of the cardiovascular autonomic neuropathy in diabetes. Diabetes, 1994, 43, 607-612.	0.3	11
362	ACETYLSALICYLIC ACID IN DIABETES. Lancet, The, 1981, 317, 560.	6.3	10
363	Impaired insulin secretion in human diabetes mellitus. I. The effect of alpha-adrenergic inhibition. Pharmacological Research Communications, 1982, 14, 217-225.	0.2	10
364	Platelet aggregation after strict metabolic control using the artificial pancreas. Diabetologia, 1982, 23, 545-545.	2.9	10
365	Effects of a Mixed Meal on Hemodynamics and Autonomic Control of the Heart in Patients with Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 194-200.	1.8	10
366	Humalog (lispro) for type 2 diabetes. Expert Opinion on Biological Therapy, 2012, 12, 1541-1550.	1.4	10
367	Can diet prevent diabetes?. Journal of Diabetes and Its Complications, 2017, 31, 288-290.	1.2	10
368	EMPATHY: A New Tool for Identifying the Most Suitable Thyroxine Formulation in Hypothyroid Patients. Thyroid, 2019, 29, 928-933.	2.4	10
369	Non-Enzymatic Glycosylation Reduces Antithrombin III Activity. Thrombosis and Haemostasis, 1984, 52, 363-363.	1.8	10
370	Induced hyperglycemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects. Diabetes, 1987, 36, 320-323.	0.3	10
371	Effect of furosemide on insulin and glucagon responses to arginine in normal subjects. Diabetologia, 1980, 18, 293-6.	2.9	9
372	Colchicine and Insulin Secretion in Man. Diabetes, 1981, 30, 1008-1012.	0.3	9
373	Acute Hyperglycemia and Autonomic Function. Diabetes Care, 2001, 24, 2016-2017.	4.3	9
374	Mediterranean diet and prevention of coronary heart disease. Journal of Endocrinological Investigation, 2002, 25, 296-299.	1.8	9
375	TSH oscillations in young patients with type 1 diabetes may be due to glycemic variability. Journal of Endocrinological Investigation, 2018, 41, 389-393.	1.8	9
376	Simplification of complex insulin therapy: a story of dogma and therapeutic resignation. Diabetes Research and Clinical Practice, 2021, 178, 108958.	1.1	9
377	Beta-endorphin-induced inhibition and stimulation of insulin secretion in normal humans is glucose dependent. Diabetes, 1988, 37, 1265-1270.	0.3	9
378	Influence of occlusal characteristics, food intake and oral hygiene habits on dental caries in adolescents: a cross-sectional study. European Journal of Paediatric Dentistry, 2018, 19, 95-100.	0.4	9

#	Article	IF	CITATIONS
379	Restoration of sensitivity to sulfonylurea after strict glycaemic control with insulin in non-obese type 2 diabetic subjects. Diab̕te & M̩tabolisme, 1991, 17, 443-7.	0.3	9
380	Protein C deficiency in insulin-dependent diabetes: a hyperglycemia-related phenomenon. Thrombosis and Haemostasis, 1990, 64, 104-7.	1.8	9
381	Daily rapid blood glucose variations may condition antithrombin III biologic activity but not its plasma concentration in insulin-dependent diabetes. A possible role for labile non-enzymatic glycation. Diabète & Métabolisme, 1987, 13, 16-9.	0.3	9
382	Further studies on the significance of circulating platelet aggregates induced by somatostatin in man. Metabolism: Clinical and Experimental, 1981, 30, 172-175.	1.5	8
383	Glycemic control with an artificial pancreas improves insulin responses to both oral and I.V. Glucose in nonobese noninsulin-dependent diabetic subjects. Acta Diabetologica Latina, 1985, 22, 203-213.	0.2	8
384	Hyperinsulinemia in offspring of non-insulin-dependent diabetes mellitus patients: The role played by abnormal clearance of insulin. Metabolism: Clinical and Experimental, 1995, 44, 1278-1282.	1.5	8
385	Defining the Role of Insulin Lispro in??the Management of Postprandial Hyperglycaemia in Patients with Type??2 Diabetes Mellitus. Clinical Drug Investigation, 2008, 28, 199-210.	1.1	8
386	A nomogram to estimate the proportion of patients at hemoglobin A1c target <7% with noninsulin antidiabetic drugs in type 2 diabetes: a systematic review of 137 randomized controlled trials with 39 845 patients. Acta Diabetologica, 2014, 51, 305-311.	1.2	8
387	Natural history of autoimmune primary ovarian insufficiency in patients with Addison's disease: from normal ovarian function to overt ovarian dysfunction. European Journal of Endocrinology, 2017, 177, 329-337.	1.9	8
388	Quality of life in Klinefelter patients on testosterone replacement therapy compared to healthy controls: an observational study on the impact of psychological distress, personality traits, and coping strategies. Journal of Endocrinological Investigation, 2021, 44, 1053-1063.	1.8	8
389	Glycosaminoglycans in human diabetes. Diabète & Métabolisme, 1983, 9, 32-4.	0.3	8
390	Prostaglandin E1 increases basal glucagon in man. Pharmacological Research Communications, 1978, 10, 813-821.	0.2	7
391	Acetylsalicylic acid augments insulin and c-peptide responses to arginine in diabetes mellitus. Prostaglandins, Leukotrienes and Essential Fatty Acids, 1979, 2, 109-110.	1.2	7
392	Somatostatin and Insulin Secretion in Man. IV. The Role of Calcium. Journal of Clinical Endocrinology and Metabolism, 1980, 51, 1298-1302.	1.8	7
393	Beta-endorphin and islet hormone release in humans: evidence for interference with cAMP. American Journal of Physiology - Endocrinology and Metabolism, 1989, 257, E361-E366.	1.8	7
394	Hypertension and ascorbic acid. Lancet, The, 2000, 355, 1272-1273.	6.3	7
395	Endothelin-1 receptor antagonists reduce cardiac electrical instability induced by high glucose in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 366, 193-197.	1.4	7
396	The Effect of Weight Loss on Endothelial Functions in Obesity: Response to Sciacqua et al Diabetes Care, 2003, 26, 2968-2969.	4.3	7

#	Article	IF	CITATIONS
397	Rituximab-induced remission of autoimmune hypophysitis and primary immune thrombocytopenia in a patient with autoimmune polyendocrine syndrome type 4. Expert Review of Endocrinology and Metabolism, 2014, 9, 313-317.	1.2	7
398	Premixed insulin regimens in type 2 diabetes: pros. Endocrine, 2017, 55, 45-50.	1.1	7
399	Up and down waves of glycemic control and lower-extremity amputation in diabetes. Cardiovascular Diabetology, 2021, 20, 135.	2.7	7
400	Normalization by sodium salicylate of the impaired counterregulatory glucagon response to hypoglycemia in insulin-dependent diabetes. A possible role for endogenous prostaglandins. Diabetes, 1985, 34, 521-525.	0.3	7
401	Haemoglobin A1 in Addicts. Annals of Internal Medicine, 1982, 96, 536.	2.0	6
402	Calcitonin modulation of insulin and glucagon secretion in man. American Journal of Physiology - Endocrinology and Metabolism, 1982, 242, E206-E213.	1.8	6
403	Does treatment of noninsulin-dependent diabetes mellitus reduce the risk of coronary heart disease?. Current Opinion in Lipidology, 1996, 7, 227-233.	1.2	6
404	Effects of surgical menopause and estrogen replacement therapy on atrio-ventricular conduction and ventricular repolarization. Maturitas, 2001, 40, 47-51.	1.0	6
405	Hyperglycemia and heart dysfunction: An oxidant mechanism contributing to heart failure in diabetes. Journal of Endocrinological Investigation, 2002, 25, 485-488.	1.8	6
406	Fitness Versus Fatness: the Debate Continues. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, e20-1; author reply e20-1.	1.1	6
407	Oral Amino Acid Administration Decreases Oxidative Stress and Improves Brachial Reactivity in Elderly Individuals. American Journal of Hypertension, 2005, 18, 858-863.	1.0	6
408	Re: Prevalence and Risk Factors for Female Sexual Dysfunction in Turkish Women. Journal of Urology, 2006, 176, 840-841.	0.2	6
409	Mediterranean dietary patterns and chronic diseases. American Journal of Clinical Nutrition, 2008, 88, 1179-1180.	2.2	6
410	Clinical Inertia and Uncertainty in Medicine—Reply. JAMA - Journal of the American Medical Association, 2011, 306, 383.	3.8	6
411	HbA1c targets for type 2 diabetes: How many, …how far!. Diabetes Research and Clinical Practice, 2012, 96, 414-415.	1.1	6
412	Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither?. Endocrine, 2015, 50, 56-60.	1.1	6
413	Personalized intensification of insulin therapy in type 2 diabetes – does a basal–bolus regimen suit all patients?. Current Medical Research and Opinion, 2016, 32, 1425-1434.	0.9	6
414	Diabetes is a cardiovascular disease, isn't it?. Diabetes Research and Clinical Practice, 2018, 135, 229-231.	1.1	6

#	Article	IF	CITATIONS
415	Effects of prostaglandin E1 and prostaglandin F2alpha on insulin and glucagon plasma levels during the intravenous glucose tolerance test in man. Diab̕te & M̩tabolisme, 1978, 4, 187-91.	0.3	6
416	Effects of acetylsalicylic acid on blood glucose, plasma FFA, glycerol, 3-hydroxybutyrate, alanine, C-peptide, glucagon and growth hormone responses to arginine in insulin-dependent diabetics. Diabète & Métabolisme, 1980, 6, 39-46.	0.3	6
417	The toxic trio: acute, chronic, and post-prandial hyperglycemia. Nutrition, Metabolism and Cardiovascular Diseases, 2001, 11, 80-3.	1.1	6
418	The effects of salbutamol on some metabolic and endocrine patterns of diabetic subjects. Pharmacological Research Communications, 1980, 12, 909-919.	0.2	5
419	CALCITONIN IN DIABETES. Lancet, The, 1980, 315, 653.	6.3	5
420	Glucagon Secretion in Patients with Hypoparathyroidism: Effect of Serum Calcium on Glucagon Release. Journal of Clinical Endocrinology and Metabolism, 1982, 54, 229-232.	1.8	5
421	Does a Common Mechanism Induce Diverse Complications of Diabetes?. Diabetes Care, 1988, 11, 372-373.	4.3	5
422	Antioxidants and Nitrate Tolerance. Circulation, 1998, 98, 1350-1353.	1.6	5
423	QTc Dispersion, Hyperglycemia, and Hyperinsulinemia. Circulation, 1999, 100, e149.	1.6	5
424	Which diet is best for diabetes?. Diabetologia, 2009, 52, 988-989.	2.9	5
425	Effects of a Mediterranean-Style Diet on the Need for Antihyperglycemic Drug Therapy in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Trial. Obstetrical and Gynecological Survey, 2010, 65, 379-380.	0.2	5
426	Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2012, 3, 99-108.	1.4	5
427	New guidelines for metabolic targets in diabetes: clinician's opinion does matter. Endocrine, 2014, 46, 431-434.	1.1	5
428	Peripheral Arterial Disease and Cardiovascular Risk. Angiology, 2015, 66, 708-710.	0.8	5
429	Comment on Edelman and Polonsky. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care 2017;40:1425–1432. Diabetes Care, 2018, 41, e17-e17.	4.3	5
430	Beyond basal-bolus insulin regimen: Is it still the ultimate chance for therapy in diabetes?. Diabetes Research and Clinical Practice, 2019, 157, 107922.	1.1	5
431	Are gliflozins the new statins for diabetes?. Diabetes Research and Clinical Practice, 2019, 153, 191-193.	1.1	5
432	Possible role for increased C4b-binding-protein level in acquired protein S deficiency in type I diabetes. Diabetes, 1990, 39, 447-449.	0.3	5

#	Article	IF	CITATIONS
433	Effect of calcitonin on glucosestimulated insulin secretion in normal, obese and prediabetic subjects. Il Farmaco Edizione Pratica, 1978, 33, 256-62.	0.0	5
434	Effect of calcitonin on insulin response to arginine in man. Diabète & Métabolisme, 1979, 5, 213-6.	0.3	5
435	Beta-endorphin and islet hormone release in type-2 diabetes mellitus the effects of normoglycemia, enkephalin, naloxone and somatostatin. Diab̕te & M̩tabolisme, 1987, 13, 618-24.	0.3	5
436	A preliminary note on inhibiting effect of alpha-tocopherol (vit. E) on protein glycation. Diabète & Métabolisme, 1988, 14, 40-2.	0.3	5
437	Medical hypothesis: cardiovascular complications of diabetes mellitus-from glucose to insulin and back. DiabAïte & Métabolisme, 1994, 20, 445-53.	0.3	5
438	Coronary artery disease in type-2 diabetes mellitus: a scintigraphic study. Diabète & Métabolisme, 1993, 19, 463-6.	0.3	5
439	Somatostatin and insulin secretion in man II. The effect of theophylline. Acta Diabetologica Latina, 1979, 16, 353-358.	0.2	4
440	Somatostatin and Insultin secretion in man. Pharmacological Research Communications, 1980, 12, 57-66.	0.2	4
441	Plasma C-peptide response to arginine in insulin-dependent diabetic subjects. Journal of Endocrinological Investigation, 1980, 3, 19-23.	1.8	4
442	Effect of calcitonin on plasma glucose, C-peptide, glucagon and growth hormone responses to arginine in insulin-dependent diabetic subjects. Acta Diabetologica, 1981, 18, 235-241.	1.2	4
443	Impaired insulin secretion in human diabetes mellitus. Effect of pharmacological activation of gamma-aminobutyric acid system. Acta Diabetologica Latina, 1986, 23, 23-28.	0.2	4
444	Hyperglycemia-Conditioned Increase in Alpha-2-Macroglobulin in Healthy Normal Subjects: A Phenomenon Correlated with Deficient Antithrombin III Activity. Acta Haematologica, 1989, 82, 61-63.	0.7	4
445	Clinical remission in patients with IDDM and family history of NIDDM. Lancet, The, 1991, 337, 1165.	6.3	4
446	Height and glucose tolerance. Diabetologia, 1992, 35, 698-699.	2.9	4
447	Lifestyle and Adiponectin Level: Four-Year Follow-up of Controlled Trials. Archives of Internal Medicine, 2010, 170, 1270.	4.3	4
448	Comment on: Wheeler et al. Macronutrients, Food Groups, and Eating Patterns in the Management of Diabetes: A Systematic Review of the Literature, 2010. Diabetes Care 2012;35:434-445. Diabetes Care, 2012, 35, e51-e51.	4.3	4
449	Linking prediabetes and cancer: a complex issue. Diabetologia, 2015, 58, 201-202.	2.9	4
450	<p>Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 777-784.	1.1	4

#	Article	IF	CITATIONS
451	Circulating endothelial progenitor cells in acromegaly. Journal of Endocrinological Investigation, 2013, 36, 825-30.	1.8	4
452	Sensorimotor evaluation of ano-rectal complex in diabetes mellitus. Diabète & Métabolisme, 1991, 17, 520-4.	0.3	4
453	Studies on the mechanism of salicylate-induced increase of insulin secretion in man. Diabète & Métabolisme, 1988, 14, 431-6.	0.3	4
454	Interaction between epinephrine, prostaglandin E, and met-enkephalin in the regulation of insulin release in man. DiabÃʿte & Métabolisme, 1985, 11, 295-302.	0.3	4
455	Non-enzymatic glycosylation reduces antithrombin III activity. Thrombosis and Haemostasis, 1984, 52, 363.	1.8	4
456	Heterogeneity of diabetes mellitus. Diabetologia, 1987, 30, 678-679.	2.9	4
457	Effects of acetylsalicylic acid on plasma glucose, free fatty acid, betahydroxybutyrate, glucagon and c-peptide responses to salbutamol in insulin-dependent diabetic subjects. Acta Diabetologica, 1981, 18, 27-36.	1.2	3
458	Influence of labile glucose adducts on glycosylated protein assay by aminophenylboronic acid affinity chromatography:In vivo studies. Acta Diabetologica Latina, 1985, 22, 79-82.	0.2	3
459	Increased Alpha-2-Macroglobulin in Opiate Addicts: Further Evidence of an Alteration in the Coagulation System due to Opiate Addiction. Acta Haematologica, 1985, 73, 117-117.	0.7	3
460	Pathophysiological study of the non-insulin-dependent phase of type I diabetes mellitus. Acta Diabetologica Latina, 1988, 25, 161-172.	0.2	3
461	The combined insulin and sulfonylurea therapy in diabetes of elderly people. Archives of Gerontology and Geriatrics, 1991, 13, 245-253.	1.4	3
462	Respiratory Function in IDDM Patients. Diabetes Care, 1993, 16, 851-852.	4.3	3
463	Plasma Endothelin in Diabetic Autonomic Neuropathy. Diabetes Care, 1994, 17, 161-162.	4.3	3
464	What to 'eat and chew' in acute myocardial infarction?: reply. European Heart Journal, 2006, 27, 1629-1630.	1.0	3
465	Optimal Treatments for the Metabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, e30.	1.1	3
466	Mediterranean Diet Inversely Associated With the Incidence of Metabolic Syndrome: the SUN Prospective Cohort: Response to Tortosa et al Diabetes Care, 2008, 31, e36-e36.	4.3	3
467	Cardiovascular Disease-Related Lifestyle Factors and Longevity. Cardiology Research and Practice, 2011, 2011, 1-2.	0.5	3
468	Lifestyle for Erectile Dysfunction: A Good Choice. Archives of Internal Medicine, 2012, 172, 296.	4.3	3

#	Article	IF	CITATIONS
469	Diabetes medications and cancer: A way out of uncertainty. Diabetes Research and Clinical Practice, 2012, 97, 175-177.	1.1	3
470	Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915-2922. Diabetes Care, 2013, 36, e180-e180.	4.3	3
471	Comment on Grunberger "Insulin Analogs—Are They Worth It? Yes!―Diabetes Care 2014;37:1767–1770 Davidson "Insulin Analogs—Is There a Compelling Case to Use Them? No!―Diabetes Care 2014;37:1771–1774. Diabetes Care, 2014, 37, e229-e230.	and 4.3	3
472	Comment on Mita et al. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Diabetes Care 2016;39:455–464. Diabetes Care, 2016, 39, e102-e103.	4.3	3
473	Metabolic effectiveness of gliflozins and gliptins in the routine clinical practice of patients with type 2 diabetes: preliminary results from GIOIA, a prospective multicentre study. Diabetes Research and Clinical Practice, 2019, 155, 107787.	1.1	3
474	Effect of insulin on blood rheology in nonâ€diabetic subjects and in patients with type 2 diabetes mellitus. Diabetic Medicine, 1997, 14, 959-963.	1.2	3
475	Particulate matter air pollution: individual choices for improving cardiometabolic well-being. Endocrine, 2018, 59, 495-498.	1.1	3
476	Oxytocin increases arginine-induced A and B cell secretion in normal man and in diabetic subjects. Diabète & Métabolisme, 1988, 14, 104-7.	0.3	3
477	Hypertension in the elderly is associated with impaired glucose metabolism independently of obesity and glucose intolerance. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 1988, 6, S45-8.	0.1	3
478	Impaired insulin secretion in human diabetes mellitus. Interactions between naloxone, phentolamine and lysine acetylsalicylate upon glucose induced insulin release. DiabÃʿte & Métabolisme, 1985, 11, 350-8.	0.3	3
479	The combination of insulin and oral hypoglycaemic drugs: a continuous challenge. Diabète & Métabolisme, 1993, 19, 219-24.	0.3	3
480	Is a family history of diabetes associated with an increased level of cardiovascular risk factors? Studies in healthy people and in subjects with different degree of glucose intolerance. DiabÃʿte & Métabolisme, 1993, 19, 230-8.	0.3	3
481	Effects of vaso-inactive doses of PGA1 and PGE1 on insulin secretion in the rat. Pharmacological Research Communications, 1977, 9, 427-436.	0.2	2
482	Acetylsalicylic acid and glucose metabolism in man: is there a role for prostaglandins?. Diabetologia, 1986, 29, 265-265.	2.9	2
483	Pregnancy as Environmental Factor Precipitating IDDM. Diabetes Care, 1989, 12, 438-440.	4.3	2
484	Evidence for a Reduced Heparin Cofactor II Biological Activity in Diabetes. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1990, 20, 357-361.	0.5	2
485	Hemorheological and cardiovascular responses to beta-endorphin and naloxone in healthy subjects and in patients with essential hypertension Journal of Clinical Endocrinology and Metabolism, 1994, 79, 826-830.	1.8	2
486	Hemorheological and cardiovascular effects of exercise training in the rehabilitation of elderly patients with chronic obstructive pulmonary disease. Archives of Gerontology and Geriatrics, 1999, 28, 1-8.	1.4	2

#	Article	IF	CITATIONS
487	Stress hyperglycaemia and death after myocardial infarction. Lancet, The, 2000, 355, 1647.	6.3	2
488	Effect of High Glucose on Vasculature. Circulation, 2003, 108, e74; author reply e74.	1.6	2
489	Virgin Olive Oil and Vegetables Improve Endothelial Health. Journal of the American College of Cardiology, 2006, 48, 413-414.	1.2	2
490	Relationship of baseline HbA _{1c} and HbA _{1c} reduction following insulin therapy in Type 2 diabetes. Diabetic Medicine, 2011, 28, 247-247.	1.2	2
491	Insulin Analogs and Glycosylated Hemoglobin Target of Less Than 7% in Type 2 Diabetes: A Systematic Review of Randomized Trials. Metabolic Syndrome and Related Disorders, 2011, 9, 167-176.	0.5	2
492	Comment on Khunti et al. Clinical Inertia in People With Type 2 Diabetes: A Retrospective Cohort Study of More Than 80,000 People. Diabetes Care 2013;36:3411–3417. Diabetes Care, 2014, 37, e113-e113.	4.3	2
493	Comment on Home et al. Predictive and Explanatory Factors of Change in HbA1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs. Diabetes Care 2014;37:1237–1245. Diabetes Care, 2014, 37, e183-e183.	4.3	2
494	The Association Between Metabolic Syndrome and Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2014, 48, 742-743.	1.1	2
495	Cardiovascular guidelines: separate career may help attenuate controversy. Cardiovascular Diabetology, 2014, 13, 66.	2.7	2
496	Dissonance among treatment algorithms for hyperglycemia in type 2 diabetes: an egalitarian dialog. Journal of Endocrinological Investigation, 2019, 42, 237-242.	1.8	2
497	Comment on Tay et al. A Very Low-Carbohydrate, Low–Saturated Fat Diet for Type 2 Diabetes Management: A Randomized Trial. Diabetes Care 2014;37:2909–2918. Diabetes Care, 2015, 38, e64-e64.	4.3	2
498	Influence of acetylsalicylic acid on insulin, glucagon and growth hormone responses to glucose and arginine in healthy subjects. Il Farmaco Edizione Pratica, 1979, 34, 131-7.	0.0	2
499	Analysis of diabetic family connection in subjects with insulin-dependent diabetes mellitus (IDDM). Diabète & Métabolisme, 1990, 16, 449-52.	0.3	2
500	Low molecular weight heparin restores antithrombin III activity from hyperglycemia induced alterations. Diabà te & Métabolisme, 1990, 16, 86-92.	0.3	2
501	In vivo andin vitro experiments on relationships between PGA1 and glucose utilization. Acta Diabetologica Latina, 1976, 13, 40-46.	0.2	1
502	Hyperglycemia Alters the Beta-Cell Sensitivity to β-Endorphin in Noninsulin-Dependent Diabetic Subjects. Hormone and Metabolic Research, 1988, 20, 306-307.	0.7	1
503	Theophylline prevents the inhibitory effect of prostaglandin E 2 on glucose-induced insulin secretion in man. European Journal of Endocrinology, 1988, 118, 187-192.	1.9	1
504	Hyperinsulinemia in glucose intolerance: Is it true?. Journal of Endocrinological Investigation, 1994, 17, 391-396.	1.8	1

#	Article	IF	CITATIONS
505	Reply to Elhadd et al. Diabetes Care, 1997, 20, 1338-1339.	4.3	1
506	Is the whole-diet approach better than a low-fat diet in cardiovascular risk reduction?. American Journal of Clinical Nutrition, 2006, 83, 921.	2.2	1
507	Pioglitazone vs Climepiride and Carotid Intima-Media Thickness. JAMA - Journal of the American Medical Association, 2007, 297, 1315.	3.8	1
508	Review: lifestyle modifications and pharmacotherapy for cardiovascular risk factors are associated with improvements in erectile dysfunction. Evidence-based Nursing, 2012, 15, 71-72.	0.1	1
509	Comment on: Raz et al. Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2013;36:1779-1788. Diabetes Care, 2013, 36, e192-e192.	4.3	1
510	Glucose, cholesterol, and blood pressure: is lower always better for type 2 diabetes?. Endocrine, 2016, 54, 32-37.	1.1	1
511	Intensive Lifestyle Intervention for Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2017, 318, 2494.	3.8	1
512	Opioid peptides and obesity. The European Journal of Medicine, 1992, 1, 90-6.	0.1	1
513	Mean red blood cell volume, narcotic addiction, and glucose tolerance. Archives of Internal Medicine, 1985, 145, 1530-1.	4.3	1
514	Glycosylated proteins as an indicator of metabolic control in diabetes: evaluation by aminophenylboronic acid affinity chromatography. Acta Diabetologica Latina, 1984, 21, 49-54.	0.2	1
515	Thrombocytopenia in heroin users. Blood, 1982, 60, 276.	0.6	1
516	Thrombocytopenia in heroin users [letter]. Blood, 1982, 60, 276-276.	0.6	1
517	Hemodynamic effects of somatostatin in insulin-dependent diabetic subjects. Acta Diabetologica Latina, 1979, 16, 331-337.	0.2	0
518	A comparative study of metabolic and hormonal responses to somatostatin and propranolol in man. Acta Diabetologica Latina, 1979, 16, 77-84.	0.2	0
519	The oxygen-release capacity of red blood cells in insulin-dependent diabetics after artificial pancreas. Acta Diabetologica Latina, 1984, 21, 281-286.	0.2	0
520	Aspirin and non-enzymatic glycation. Acta Diabetologica Latina, 1987, 24, 171-172.	0.2	0
521	Atypical environmental factor in expressing type I (insulin-dependent) diabetes mellitus. Journal of Endocrinological Investigation, 1990, 13, 79-79.	1.8	0
522	Hormonal and Metabolic Effects of Beta-Endorphin in the Elderly. Hormone and Metabolic Research, 1991, 23, 351-352.	0.7	0

#	Article	IF	CITATIONS
523	Isolated Fatty Change of Liver as Marker of Glucose Intolerance. Diabetes Care, 1992, 15, 1438-1439.	4.3	Ο
524	Combination Therapy in NIDDM. Diabetes Care, 1993, 16, 1625-1626.	4.3	0
525	Response to Cantero. Diabetes Care, 1998, 21, 327-327.	4.3	0
526	Oxidative Stress and Cardiovascular Complications of Diabetes. , 1998, 14, 78-90.		0
527	Hyperglycemia leads to ECG reevaluation. Aging Clinical and Experimental Research, 2000, 12, 246-248.	1.4	0
528	The obese Etruscan. Journal of Endocrinological Investigation, 2001, 24, 206-206.	1.8	0
529	";The visceral fat of Bek, Pharaoh's sculptor― Journal of Endocrinological Investigation, 2001, 24, 836-836.	1.8	Ο
530	Reply to MR Goldstein. American Journal of Clinical Nutrition, 2001, 74, 272-273.	2.2	0
531	Letter Regarding Article by Ferriera et al, "Postprandial Hypertriglyceridemia Increases Circulating Levels of Endothelial Cell Microparticles― Circulation, 2005, 111, e457-8; author reply e457-8.	1.6	Ο
532	Statins, Diet, and Low Cholesterol. JAMA - Journal of the American Medical Association, 2006, 295, 2479.	3.8	0
533	Which Mediterranean Diet in the Management of Metabolic Syndrome?. Archives of Internal Medicine, 2009, 169, 1069.	4.3	Ο
534	Low-Carbohydrate Diet and Blood Lipid Levels: How Good and How Fast?. Archives of Internal Medicine, 2009, 169, 1930.	4.3	0
535	Adding Noninsulin Antidiabetic Drugs to Metformin Therapy for Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2010, 304, 405.	3.8	Ο
536	A (hi)story <i>pour les analphabètes–</i> of Larissa Sansour's video. Third Text, 2011, 25, 301-309.	0.3	0
537	Comment on Krul-Poel et al. Effect of Vitamin D Supplementation on Glycemic Control in Patients With Type 2 Diabetes (SUNNY Trial): A Randomized Placebo-Controlled Trial. Diabetes Care 2015;38:1420–1426. Diabetes Care, 2015, 38, e168-e168.	4.3	0
538	From pump to sink: The hydraulic connection of type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 159, 107772.	1.1	0
539	Arguments for an inhibiting role of prostaglandin E1 on insulin secretion in man. Il Farmaco; Edizione Scientifica, 1979, 34, 157-64.	0.0	0
540	Relationships between growth hormone secretion and microangiophaty in subjects with prediabetes. Il Farmaco; Edizione Scientifica, 1979, 34, 709-15.	0.0	0

#	Article	IF	CITATIONS
541	Moderate coffee consumption seems to cause no danger for coronary heart disease. Diabète & Métabolisme, 1990, 16, 525-6.	0.3	0
542	Increased beta-thromboglobulin levels in heroin addicts. Thrombosis and Haemostasis, 1985, 54, 550.	1.8	0
543	Increased labile hemoglobin glycosylation in opiate addicts: an unclear phenomenon. DiabÃʿte & Métabolisme, 1985, 11, 189-90.	0.3	0
544	Somatostatin and insulin secretion in man. III - Lack of interaction with prostaglandins. Il Farmaco; Edizione Scientifica, 1980, 35, 615-20.	0.0	0
545	Circulating platelet aggregates induced by somatostatin in insulin-dependent diabetic subjects. Diabète & Métabolisme, 1980, 6, 245-9.	0.3	0
546	Rapid decrease of platelet aggregation (ADPand collageninduced) and of platelet circulating aggregates by the artificial pancreas in insulin-dependent diabetics. Diabète & Métabolisme, 1984, 10, 31-5.	0.3	0
547	Impaired insulin secretion in human diabetes mellitus III. The effect of the serotonin antagonist metergoline. Diabète & Métabolisme, 1981, 7, 231-4.	0.3	0
548	The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al. Diabetes Care, 2006, 29, 175-6; author reply 177-8.	4.3	0
549	Colchicine and insulin secretion in man. Diabetes, 1981, 30, 1008-1012.	0.3	0
550	Applications for social security benefits related to diabetes in the working age in Italy between 2009 and 2019: a nationwide retrospective cohort study. BMJ Open, 2022, 12, e057825.	0.8	0